Diffusion Pharmaceutical LLC
  • Email
  • Facebook
  • Twitter
  • Rss
  • Home
  • About
    • Introduction
    • Executive Summary
    • Management
    • Board of Directors
    • Investors
      • Investor Information Log-In
      • Potential Investor Registration
    • Intellectual Property
    • Useful Links
  • Cancer Treatment
    • Overview/The Problem
    • Treatment Resistance in Cancer
    • Tumor Sensitization and TSC
    • Preclinical Results
  • Clinical Trials
    • Clinical Trials Overview
  • Publications
    • Cancer
    • Cardiovascular and Stroke
    • Hemorrhagic Shock
    • Other
  • Programs
    • Program Overview
    • Glioblastoma Program
    • Brain Metastasis Program
    • Other Indications For TSC
  • News
    • Press Releases
    • Subscribe
  • Contact
    • Contact
    • Directions

Publications

  • Cancer
  • Cardiovascular and Stroke
  • Hemorrhagic Shock
  • Other

Hemorrhagic Shock

Stennett A, Murray R, Roy J, Gainer J. Trans-sodium crocetinate and hemorrhagic shock. Shock. 2007; 28(3):339-344.

Roy JW, Graham MC, Griffin AM, Gainer JL. A novel fluid resuscitation therapy for hemorrhagic shock. Shock. 1998; 10:213-217.

Giassi LJ, Gilchrist MJ, Graham MC, Gainer JL. Trans-sodium crocetinate restores blood pressure, heart rate, and plasma lactate after hemorrhagic shock. J Trauma. 2001; 51:932-938.

Giassi LJ, Poynter AK, Gainer JL. Trans sodium crocetinate for hemorrhagic shock: effect of time delay in initiating therapy. Shock. 2002; 18:585-588.

Stennett AK, Gainer JL. TSC for hemorrhagic shock: effects on cytokines and blood pressure. Shock. 2004; 22:569-574.

Stern SA, Zink B J, Wang X, Mertz M. The effects of resuscitation with trans-sodium crocetinate in a model of combined hemorrhagic shock and traumatic brain injury. Acad Emerg Med. 2002; 9:415-416, Abstract.

  • Office: 434-220-0718
  • Contact Us
    • Facebook
    • Email
© 2012 Diffusion Pharmaceutical LLC


Charlottesville SEO